The Legislation for Biodiversity Conservation in China

Effectivebiodiverdityconservationneedsasoundlegalsystemthatincludesthelegisla-tionininternational,nationalandlocallevels.TheConventiononBiologicalDiversity(CBD)thatenteredintoforceonDecember29,1993,isaninternationallegalinstrument.Asaframeconvention,ithasformedalegalsystem,togetherwiththeotherinternationalagree-mentssuchastheConventiononWetlandsofInternationalImportanceEspeciallyasWater-fowlHabitat(Ramsar1971),theConventionConcerningtheProtectionoftheWorldCul-turalandNaturalHeritage(P…     

用地高辛标记探针检测基因工程人β干扰素制品中的外源DNA

基因工程人β干扰素工程菌经发酵培养、纯化后获得纯的制品,采用斑点杂交技术,用非放射性地高辛标记超声裂解的全工程菌ＤＮＡ作为探针,检测基因工程人β干扰素纯品,结果显示：基因工程人β干扰素纯品中的外源ＤＮＡ含量小于１００ｐｇ／剂。     

虎耳草科落新妇族的研究

本文探讨了落新妇族Trib．Astilbeae的系统发育和地理分布。依据进化论、被子植物性状演化总趋势和外类群比较,确认了该族及其外类群Penthorum的重要性状(染色体基数,花粉纹饰,胎座式,心皮、雄蕊、花瓣和萼片数目,萼片脉型,叶型)的极性。采用徐克学(1989)最大同步法做了分支分析,推导出了该族的系统树图。系统树图表明：Rodgersia和Astilboides是一单系类群,而Astilbe为其姊妹群; Rodgersia较Astilbe进化,Astilboides则居二者之间;Penthorum是落新妇族的姊妹群,且与之有共同祖先。迄今为止,已知落新妇族共有24种和13变种(原变种除外)。分布于Takhtajan(1986)的东亚区、大西洋-北美区、伊朗-土兰区和马来西亚区。在东亚区,日本、朝鲜和中国(吉林-辽宁东部)有3属、17种和变种,占该族种与变种总数的45．9％,其中,含有不同演化水平的类群和该族原始种有Astilbe platyphylla,A.simplicifolia和Rodgersia podophylla,此地区是该族的起源中心、现代分布中心和分化中心。 横断山地区有2属、11种和变种,占29．7％,是另一现代分布中心。本族较进化的种Astilbe biternata、A. indica、A.khasiana和Rodgersia nepalensis等,均出现于远离起源中心地区。据此推断,本族植物的散布路线可能是从日本、朝鲜和中国(吉林-辽宁东部)向北通过东西伯利亚和白令陆桥,继而向东南进入北美东南部;向南经中国南部至菲律宾和爪哇,向西南越秦岭-大巴山山地、横断山,入喜马拉雅。落新妇属 Astilbe和鬼灯檠属Rodgersia均分布于亚洲大陆和日本岛屿,而日本于晚第三纪以来,即与亚洲大陆分离,故落新妇属和鬼灯檠属的形成,当在日本与亚洲大陆分离之前。据此推知,落新妇族的起源时间可能在早第三纪,或可追溯至晚白垩纪。     

Search for the possible role of ‘immunotherapy’ in operable bronchial non-small cell carcinoma (stage I and II): A phase I study with Corynebacterium parvum intrapleurally

Summary The possibility of giving C. parvum intrapleurally (i.p.) was investigated. C. parvum was given post-operatively either i.p. only or i.p. and intravenously (i.v.) simultaneously. The dose varied from 0.1–10 mg i.p. All patients had been operated for a bronchial carcinoma. Results: (1) Subjective complaints of either dyspnoea, thoracic pain, chills or nausea occured in 31 of 63 patients. No clear dose relation was found. A feeling of discomfort and fever could occur for another 3–4 days after the above more acute symptoms had disappeared. (2) Increased fever (0.5° C) occurred in 71% of the patients injected i.p. only. (3) No anaphylactic reaction was observed. (4) Increased total white blood cell counts (<20%) occurred in 38 patients. The WBC increase was mainly due to higher number of neutrocytes and granulocytes. Total lymphocyte, monocyte, eosinophilic, and basophilic granulocytes values per mm³ circulating blood remained unchanged, except at the dose of 7 mg C. parvum i.p. when monocyte values were increased significantly from 576±247 to 1100±578/mm³. (5) Moderate to severe effusions were observed radiologically in three patients after C. parvum intrapleurally.The study group is: M. Kaufmann, J. Stjernswärd (Ludwig Institut for Cancer Research, Lausanne Branch, Switzerland), M. Zelen, K. Stanley (Frontier Science and Technology Research Foundation, Inc. Amherst, New York, USA), D. S. Freestone, R. Bomford, M. T. Scott, T. Priestman (The Wellcome Research Laboratory, Beckenham, England), C. Mouritzen, G. Ahlbom (Dept. of Thoracic and Cardiovascular Surgery, Aarhus Kommunehospital, Aarhus, Denmark), N. Konietzko, D. Greschuchna (Ruhrland Klinic, Essen-Haidhausen, Germany), P. Hilgard (Innere Klinik und Poliklinik [Tumorforschung] Essen, Germany), J. Vogt-Moykopf, D. Zeidler, H. Toomes (Thoraxchirurgische Spezial-Klinik, Heidelberg-Rohrbach, Germany), F. Krause, R. Rios (Thoraxchirurgische Abt., Fachkrankenhaus für Lungen- und Bronchialerkrankungen, Löwenstein, Germany), J. Orel, M. Benedik, B. Hrabar (Clinical Center, Dept. of Thoracic Surgery, Ljubljana, Yugoslavia), S. Plesnicar (The Institute of Oncology, Ljubljana, Yugoslavia), H. A. Rostad, J. R. Vale (Rikshospital, Oslo, Norway), S. Hagen, S. Birkeland, (Ulleval Hospital, Oslo, Norway), T. Harbitz, R. Nissen-Meyer (Aker Hospital, Oslo, Norway), L. Rodriguez, V. O. Björk, K. Böök (Karolinska Sjukhuset, Thoracic Clinic, Stockholm, Sweden), E. Gradel, J. Hasse, P. Holbro (Kantonsspital, Thoraxchirurgische Klinik, Basel, Switzerland), L. Eckmann (Tiefenauspital, Chir. Univ.-Klinik, Bern, Switzerland), B. Nachbur, T. Liechti (Inselspital, Dept. of Thoracic and Cardiovascular Surgery, Bern, Switzerland), H. Cottier (Inst. of Pathology, Inselspital, Bern, Switzerland), W. Maurer, M. Kaufmann, P. Froelicher (Bürgerspital, Surgical Dept., Solothurn, Switzerland), H. Denck, N. Pridun (Krankenhaus der Stadt Wien-Lainz, Chir. Abt., Vienna, Austria), K. Karrer (Institute for Cancer Research, University of Vienna, Austria) Reprint requests should be addressed to any of the members listed above, or to the Ludwig Lung Cancer Trial, Operation Office, LICR, CH-1066 Epalinges, Switzerland. (For Current Contents, etc., please use above address)     

正常大鼠肾脏细胞溶酶体膜的构成蛋白

溶酶体是细胞内对其吞噬之物质溶解及消化之主要场所,同时也是细胞自噬作用的主要细胞器。为了进一步了解此细胞器的功能与结构,我们采用免疫荧光标记法,通过5种针对大鼠肝细胞溶酶体膜蛋白的特异性单克隆抗体,对大鼠正常肾脏细胞溶酶体膜蛋白进行了标记,并通过NH_4Cl溶液对溶酶体作了膜膨胀处理,结果显示:(1)细胞内溶酶体膜蛋白是由多种蛋白所构成,其各种蛋白的含量是不同的;(2)所有溶酶体膜蛋白均表达于该细胞器之表面;(3)NH_4Cl溶液能有效地使溶酶体扩张,这将有和于进一步研究溶酶体的结构。     

中国寻螨属一新种记述(蜱螨亚纲:长须螨科)

寻螨属Zetzellia在中国曾报道了两种:苹果寻螨Z.mail(Ewing)和北京寻螨Z.beijing Wang and Xu1987.本文描述了寻螨属一新种,庐山寻螨Z.lushanensis sp.nov.模式标本保存于江西大学生物系.文内测量单位为μm。     

应用杆状病毒载体在昆虫细胞系统中表达乙型肝炎病毒表面抗原基因

构建了同时带有乙型肝炎病毒表面抗原基因和大肠杆菌的β-半乳糖苷酶基因的杆状病毒转移载体质粒pVL941lacHBS。应用磷酸钙沉淀技术将pVL941lacHBS DNA转入事先用AcNPV感染过的Sf9细胞,在显色剂X-gal存在下,筛选无多角体的蓝色蚀斑。经过若干次蚀斑纯化,最后获得含乙肝病毒表面抗原基因和β-半乳糖苷酶基因的重组杆状病毒R-AcV941LS。 用R-AcV941LS感染Sf9细胞,在感染后72～96小时,用RPHA和RIA分别检测组织培养上清液和细胞裂解液中的乙型肝炎病毒表面抗原含量。结果,组织培养上清液为3.83μg/1×10~6～2×10~6细胞;细胞裂解液为4.39μg/1×10~6～2×10~6细胞。乙型肝炎病毒表面抗原的合成总量为8.22μg/1×10~6～2×10~6细胞。免疫电镜观察显示表达产物呈约22nm的球形颗粒。小鼠免疫接种实验结果表明,以R-AcV941LS感染Sf9细胞表达的乙型肝炎病毒表面抗原与在哺乳动物细胞系表达的乙型肝炎病毒表面抗原具有相近似的免疫原性。